Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays

The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enablin...

Full description

Saved in:
Bibliographic Details
Published inMicrobiology spectrum Vol. 13; no. 3; p. e0203324
Main Authors Iglesias-Ussel, Maria D., Bowie, Aleah, Anderson, Jack G., Li, Yin, Park, Lawrence P., Cardona, Jose F., Dennis, Patrick, Ebuh, Valentine, Geller, Steven A., Jain, Manish, McKenzie, Mark M., Merchant-Borna, Kian, Patel, Anand, Siegel, Amy, Strauss, Guy S., Thoppil, Joby J., Weinberg, Aaron S., Woods, Christopher W.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 04.03.2025
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Child
COVID-19
COVID-19 - diagnosis
COVID-19 Nucleic Acid Testing - methods
COVID-19 Testing - methods
Female
Humans
ID NOW
isothermal
Male
Middle Aged
Molecular Diagnostic Techniques - methods
POC
Point-of-Care Systems
Point-of-Care Testing
Prospective Studies
Real-Time Polymerase Chain Reaction - methods
Research Article
rRT-PCR
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - isolation & purification
Sensitivity and Specificity
Special Series: Laboratory Equity
Virology
Young Adult
COVID-19
SARS-CoV-2
rapid testing
POC
nicking endonuclease amplification reaction (NEAR)
isothermal
ID NOW
rRT-PCR
Online AccessGet full text

Cover

More Information
Summary:The Abbott ID NOW TM COVID-19 2.0 assay is a suitable rapid test for diagnosing COVID-19 in acute symptomatic subjects and can be used in point-of-care settings and low-resource settings. With results reported in 12 minutes or less, Abbott ID NOW TM COVID-19 2.0 facilitates timely diagnosis, enabling linkage to appropriate antiviral medication.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Yin Li is a Senior Principal Biostatistician at Abbott Laboratories. Kian Merchant-Borna has served on scientific advisory boards for Abbott Diagnostics unrelated to the submitted work. Each author's institution received financial support for the performance of the study. Christopher W. Woods is employed and holds equity in Biomeme. He is on the advisory board for FHI Clinical and is a member of the Board of Directors for Global Health Innovation Alliance Accelerator.
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.02033-24